Alpha 2.0
Login Register
» Articles » PMID: 36844131

S53P4 BIOACTIVE GLASS PUTTY IN THE LOCAL TREATMENT OF CAVITARY CHRONIC OSTEOMYELITIS

Overview
Journal Acta Ortop Bras
Specialty Orthopedics
Date 2023 Feb 27
PMID 36844131
Authors
Gabriela Nagy Baldy Dos Reis
Gabriel Trova Cuba
Walter Hamilton de Castro Targa
Paulo Sergio Contador Miras
Jose Carlos Bongiovanni
Mauro Jose Salles
Fernando Baldy Dos Reis
Adriana Macedo DellAquila
Affiliations
Soon will be listed here.
Abstract

Objective: Evaluating the clinical results of bioactive glass S53P4 putty for the treatment of cavitary chronic osteomyelitis.

Methods: Retrospective observational study, including patients of any age with clinical and radiological diagnosis of chronic osteomyelitis, who underwent surgical debridement and implantation of bioactive glass S53P4 putty (BonAlive Putty, Turku, Finland). Patients who underwent any plastic surgery on the soft tissues of the affected site or had segmental bone lesions or septic arthritis were excluded. Statistical analysis was performed using Excel. Demographic data, as well as data on the lesion, treatment, and follow-up, were collected. Outcomes were classified as "disease-free survival," "failure," or "indefinite."

Results: This study included 31 patients, of which 71% were men and had with a mean age of 53.6 years (SD ± 24.2). In total, 84% were followed-up for at least 12 months and 67.7% had comorbidities. We prescribed combination antibiotic therapy for 64.5% of patients. In 47.1%, was isolated. Finally, we classified 90.3% of cases as "disease-free survival" and 9.7% as "indefinite."

Conclusion: Bioactive glass S53P4 putty is safe and effective to treat cavitary chronic osteomyelitis, including infections by resistant pathogens, such as methicillin-resistant .

Citing Articles

Ion release, cytocompatibility and microbial inhibition of a novel varnish containing fluoride-doped bioactive glass ceramics: an in vitro study.

Maciel P, de Medeiros E, Figueiredo L, Dias R, de Araujo E, Batista R Clin Oral Investig. 2025; 29(2):132.

PMID: 39956879 DOI: 10.1007/s00784-025-06202-x.

Initial therapeutic evidence of a borosilicate bioactive glass (BSG) and FeO magnetic nanoparticle scaffold on implant-associated bone infection.

Jin Y, Liu H, Chu L, Yang J, Li X, Zhou H Bioact Mater. 2024; 40:148-167.

PMID: 38962659 PMC: 11220464. DOI: 10.1016/j.bioactmat.2024.05.040.

Outcome and Predictors of Treatment Failure in Chronic Osteomyelitis Using Bioactive Glass Granules and Putty Formulations.

DellAquila A, Reis G, Cuba G, Targa W, Bongiovanni J, Durigon T Antibiotics (Basel). 2023; 12(12).

PMID: 38136754 PMC: 10740565. DOI: 10.3390/antibiotics12121720.

References
1.
Filipovic U, Dahmane R, Ghannouchi S, Zore A, Bohinc K . Bacterial adhesion on orthopedic implants. Adv Colloid Interface Sci. 2020; 283:102228. DOI: 10.1016/j.cis.2020.102228. View
2.
Drago L, De Vecchi E, Bortolin M, Toscano M, Mattina R, Romano C . Antimicrobial activity and resistance selection of different bioglass S53P4 formulations against multidrug resistant strains. Future Microbiol. 2015; 10(8):1293-9. DOI: 10.2217/FMB.15.57. View
3.
Bernard L, Dinh A, Ghout I, Simo D, Zeller V, Issartel B . Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. Lancet. 2014; 385(9971):875-82. DOI: 10.1016/S0140-6736(14)61233-2. View
4.
Osmon D, Berbari E, Berendt A, Lew D, Zimmerli W, Steckelberg J . Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2012; 56(1):1-10. DOI: 10.1093/cid/cis966. View
5.
Cunha M, Murca M, Nigro S, Klautau G, Salles M . In vitro antibacterial activity of bioactive glass S53P4 on multiresistant pathogens causing osteomyelitis and prosthetic joint infection. BMC Infect Dis. 2018; 18(1):157. PMC: 5883601. DOI: 10.1186/s12879-018-3069-x. View